Indian pharmaceutical stocks took a hit as Trump’s threat of imposing tariffs on pharma imports spooked investors. Despite India’s strong presence in the US generics market, potential tariffs may increase costs for US consumers and create supply chain challenges.
12 equity mutual funds with over Rs 1,000 NAV offer upto 24% CAGR since their inception. Do you own any?
Out of these 12 funds, 11 have been in the market for more than 25 years. They have delivered consistent double-digit returns over decades, highlighting
March 4, 2026